• Copper Single-Atom MOFs Enable Ultrasound-Enhanced CDT Imagi

  2026-04-27

  This study introduces a copper single-atom-based metal–organic framework (MOF) engineered for ultrasound-enhanced chemodynamic therapy (CDT) and tumor imaging. By maximizing catalytic efficiency and minimizing off-target toxicity, the authors demonstrate real-time, NIR-II-guided tumor targeting and potent ROS generation, paving the way for precision nanocatalytic cancer therapy.

• Cyclophosphamide: Mechanistic Precision and Strategic Impact

  2026-04-27

  Explore how Cyclophosphamide, a gold-standard alkylating chemotherapeutic agent, bridges advanced mechanistic understanding and translational strategy. This thought-leadership piece integrates recent protocol advances, workflow optimization, and evidence-based translational guidance for cancer and autoimmune disease research. Discover how APExBIO’s Cyclophosphamide sets new standards for reproducibility, clinical relevance, and workflow reliability.

• 3-Deazaadenosine (B6121): Scenario-Driven Solutions in Methy

  2026-04-26

  This article explores how 3-Deazaadenosine (SKU B6121) addresses real laboratory challenges in cell viability, methylation inhibition, and preclinical antiviral assays. Drawing from validated literature and practical workflow insights, we demonstrate how this S-adenosylhomocysteine hydrolase inhibitor ensures reproducibility, sensitivity, and practical ease-of-use for biomedical researchers.

• Tofacitinib Citrate (CP-690550 Citrate) in Immune Assays

  2026-04-25

  Tofacitinib citrate (CP-690550 citrate) is a highly selective JAK3 inhibitor uniquely positioned for immune regulation and inflammatory disorder research. This article delivers stepwise experimental workflows, protocol enhancements, and troubleshooting insights, translating cutting-edge cardiovascular and endothelial findings into practical guidance for superior assay design.

• Propidium Iodide: Precision DNA Intercalating Dye for Cell A

  2026-04-24

  Propidium iodide (PI) delivers rapid, quantitative insight into cell viability and apoptosis, uniquely distinguishing necrotic and late apoptotic cells in complex samples. APExBIO’s PI (SKU B7758) stands out for reproducibility and robust fluorescence, making it a top choice for advanced flow cytometry and immunological investigations.

• Cy7 NHS Ester: Technical Guide for Near-Infrared Protein Lab

  2026-04-24

  Cy7 NHS ester (SKU A8109) addresses the need for reliable, water-soluble near-infrared labeling of proteins and peptides, especially for in vivo and live cell imaging workflows where protein stability and minimized background are critical. It should not be used for applications requiring long-term solution storage or labeling of biomolecules lacking accessible amino groups.

• Puromycin Aminonucleoside: Strategic Insights for Translatio

  2026-04-23

  This thought-leadership article explores the mechanistic, experimental, and translational underpinnings of Puromycin aminonucleoside as a precision nephrotoxic agent. By integrating podocyte biology, recent EMT research, and strategic workflow guidance, we chart a path for translational teams to optimize nephrotic syndrome modeling and bridge preclinical rigor with clinical relevance. APExBIO’s product line is highlighted as a benchmark for reliability and scalability in renal pathology research.

• Bortezomib (PS-341): Reliable Solutions for Cell-Based Assay

  2026-04-23

  This article delivers scenario-driven guidance on deploying Bortezomib (PS-341) (SKU A2614) for reproducible apoptosis and proteasome-regulated cellular process assays. By addressing real-world experimental challenges with evidence-based analysis and literature-backed quantitative data, researchers can optimize workflow reliability and interpretability. Emphasis is placed on vendor selection, protocol parameters, and troubleshooting to support confident use of Bortezomib (PS-341) in advanced biomedical research.

• Cisplatin (CDDP): Applied Workflows and Troubleshooting in C

  2026-04-22

  Cisplatin (CDDP) is more than a DNA crosslinker—its precise handling and mechanistic nuances unlock advanced studies in apoptosis, chemoresistance, and tumor immunity. This guide distills state-of-the-art protocols, troubleshooting tips, and actionable insights for maximizing Cisplatin’s value in translational oncology.

• Z-YVAD-FMK: Advanced Caspase-1 Inhibitor for Pyroptosis Rese

  2026-04-22

  Z-YVAD-FMK enables precise, selective inhibition of caspase-1, driving innovation in apoptosis and pyroptosis workflows. Its robust performance in cancer and inflammasome studies, along with practical troubleshooting strategies, positions it as an essential tool for advanced cell death research.

• Sunitinib in Advanced Cancer Models: Beyond Classical RTK In

  2026-04-21

  Explore Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, in the context of ATRX-deficient tumors and advanced cellular models. This article uniquely bridges molecular mechanism with strategic assay design for impactful oncology research.

• Evaluating Drug-Induced Cancer Cell Responses: Fractional vs

  2026-04-21

  Schwartz's dissertation introduces a critical distinction in in vitro drug response assessment, demonstrating that relative viability and fractional viability capture different facets of cancer cell response to treatment. The work provides a nuanced framework for evaluating anti-cancer agents, with direct implications for experimental design and translational research.

• Cell Counting Kit-8 Plus: Sensitive WST-8 Tetrazolium Salt A

  2026-04-20

  Cell Counting Kit-8 Plus empowers researchers to rapidly quantify cell viability and cytotoxicity with high sensitivity, thanks to its advanced WST-8 chemistry and optimized workflow. Designed for robust performance across diverse applications—from drug screening to mechanistic dehydrogenase studies—this kit delivers reproducible results and seamless integration into both routine and advanced experimental pipelines.

• Bufalin Targets STK33 to Suppress Triple-Negative Breast Can

  2026-04-20

  This study identifies serine/threonine kinase 33 (STK33) as a direct molecular target of Bufalin in triple-negative breast cancer (TNBC). By elucidating Bufalin's mechanism in degrading STK33 and inhibiting TNBC cell proliferation, the research provides a new therapeutic strategy and expands the molecular understanding of Bufalin as an apoptosis inducer in cancer cells.

• IWR-1-endo: Wnt Signaling Inhibitor for Precision Cell Assay

  2026-04-19

  IWR-1-endo enables highly specific and reproducible inhibition of the Wnt/β-catenin pathway, streamlining advanced workflows in colorectal cancer and regenerative biology. This guide details optimal protocols, real-world troubleshooting, and critical insights from recent single-nucleus profiling studies, positioning IWR-1-endo as a benchmark tool for dissecting Wnt-driven mechanisms.

449 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page